Emtricitabine/tenofovir )

Phase 3Small molecule

Merck & Co.

Emtricitabine/tenofovir ) is one of 65 small molecule programs targeting Immunodeficiency. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunodeficiencyActive, not recruiting

COVID-19Active, not recruiting

ImmunodeficiencyPhase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Emtricitabine/tenofovir )

Merck & Co.

Phase 3

1 2

Bnt162b2

BioNTech

Preclinical

29 3

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 4

Rayaldee

OOrganon and Co

Preclinical

1 5

Glucocorticoid

AbbVie

Preclinical

1 6

Nadroparin

GSK

Preclinical

1 7

Statins

Sanofi

Preclinical

1 8

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 9

Olokizumab

UCB

Preclinical

1 10

Conventional

PPopulation Health Research Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Human Immunodeficiency Virus (HIV)

NCT07071623

Clinical

Trials by Indication[1]

Prophylaxis2 trials

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT01769456·78 enrolled

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT01772823·200 enrolled

PrEP1 trial

Factors Affecting PrEP Adherence

Completed·UUniversity of North Carolina, Chapel Hill··NCT02411630·167 enrolled

COVID-191 trial

Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel

Completed·PPlan Nacional sobre el Sida (PNS)·Phase 3·NCT04334928·1,002 enrolled

Human Immunodeficiency Virus (HIV)1 trial

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07071623·4,580 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Emtricitabine/tenofovir ). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Emtricitabine/tenofovir ) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Emtricitabine/tenofovir ). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Emtricitabine/tenofovir )

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Prophylaxis2 trials

PrEP1 trial

COVID-191 trial

Human Immunodeficiency Virus (HIV)1 trial

References

Drug Info

Quick Facts

Related News